Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.24 Analyst target: $12.00 Upside: 867.74%
Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy, utilizing its proprietary technology platform to develop advanced cell-based therapies for oncology and degenerative conditions. With a robust pipeline of therapeutics aimed at addressing critical unmet medical needs, Pluri actively forms strategic collaborations that bolster its research and development capabilities. Committed to revolutionizing patient care, Pluri is well-positioned to become a significant contributor in the biotechnology landscape, driving growth and delivering impactful healthcare solutions.
See the full interactive analysis & chart →Informational only — not investment advice.